Premium
Therapeutic Metabolomics Identifies Novel Treatments for Multiple Sclerosis and Chronic Pain
Author(s) -
Siuzdak Gary
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.69.3
Subject(s) - metabolomics , metabolome , context (archaeology) , computational biology , proteomics , proteome , multiple sclerosis , chemistry , biology , bioinformatics , biochemistry , paleontology , immunology , gene
Quantitative global analysis of endogenous metabolites from cells, tissues, fluids or whole organisms ‐ metabolomics, is becoming an integral part of functional genomics efforts as well as a tool for finding diagnostic biomarkers. Where the genome and proteome is largely enabled by the predictable fragmentation pattern of peptides, metabolomics is complicated by the tremendous chemical diversity of metabolites. The experimental aim in our global metabolomics studies is to obtain a comprehensive quantitative, unbiased, view of the metabolome. We have explored multiple novel mass spectrometry platforms for metabolomics including both solution‐based approaches and surface‐based mass spectrometry, such as nanostructure‐initiator mass spectrometry (NIMS). These platforms will also be presented in the context of specific biochemical applications such as chronic pain, multiple sclerosis and tissue imaging.